Targeting Sleep Deficits to Restore Memory Function in Alzheimer's Disease

About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
July 01, 2021 - June 30, 2024
Grant ID
A2021001F
Mentor(s)
Ksenia Kastanenka, PhD, Massachusetts General Hospital
Brian Backai, PhD, Massachusetts General Hospital
Goals
We aim to improve memory function in Alzheimer’s disease by improving sleep quality. This will be achieved by activating a specific group of neurons whose activity is impaired in Alzheimer’s disease. A particular period during sleep that is termed slow-wave sleep is associated with memory performance and is also disrupted in Alzheimer’s disease. Scientific evidence suggests that a specific group of neurons are responsible for slow-wave sleep regulation. This project aims to improve the function of these neurons through two different approaches. The first approach will utilize a novel technology to activate these neurons, followed by assessing memory in Alzheimer’s disease animal models. The second approach will rely on pharmacological approaches to support the function of these neurons.
Summary
Although numerous efforts have been attempting to find a cure for Alzheimer’s disease by targeting the traditional disease hallmarks, no treatment is currently available. Therefore, new approaches to target disease pathology are urgently needed. Sleep is disrupted early in the course of the disease. A particular period during sleep that is termed slow-wave sleep is closely associated with memory performance in healthy individuals and is also disrupted in Alzheimer’s disease. Scientific evidence suggests that a particular group of neurons are responsible for slow-wave sleep regulation. This project aims to find and activate this group of neurons and improve their function in Alzheimer’s disease mouse models through two different approaches. The first approach will utilize a novel genetic technology to activate these neurons with light, followed by assessing memory and pathology of Alzheimer’s disease in animals. This method will provide an essential proof of concept for the role of these neurons in Alzheimer’s disease-related sleep deficits. The second approach will rely on pharmacological approaches to support the function of these neurons. If successful, this method will be easier to translate to the clinic. The outcome of these experiments will allow us to understand the role of sleep in Alzheimer’s disease and offer a new therapeutic target for Alzheimer’s disease.
Unique and Innovative
We use state-of-the-art technology such as optogenetics which allows us to control neuronal activity using light. In addition, we also use multiphoton microscopy to image the brain in action in living animals.
Foreseeable Benefits
Our study has two foreseeable benefits to the public. First, it will increase our understanding of the role of sleep in Alzheimer’s disease and, therefore, will lead and direct future research efforts in the field. Second, our experiments can potentially lead to a discovery of a successful therapeutic for Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
The Effect of Alzheimer's Disease on Neurons Across the Sleep/Wake Cycle
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Md Joynal Abedin, PhD
The Effect of Alzheimer's Disease on Neurons Across the Sleep/Wake Cycle
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Md Joynal Abedin, PhD
Alzheimer's Disease Research
Identifying the Mechanisms That Underlie Tau Aggregation and Neurotoxicity
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Sarah Kaufman, MD, PhD
Identifying the Mechanisms That Underlie Tau Aggregation and Neurotoxicity
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Sarah Kaufman, MD, PhD
Alzheimer's Disease Research
Circadian Rhythm Disruption and Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Ashish Sharma, PhD, MPharm
Circadian Rhythm Disruption and Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Ashish Sharma, PhD, MPharm